Notification

---

Dear Reader!

Intuitive Surgical After the Q2 Selloff: When a Great Business Goes on Sale, It Never Feels Comfortable

There is an old truth in this business that every experienced investor eventually learns the hard way: the market does not sell off great companies when the news is obviously bad. It sells them off when the news is good, but the story gets complicated. That is exactly what happened to Intuitive Surgical last week.

On Thursday, July 16, the company reported second quarter results that beat Wall Street on every line that matters. Revenue of $2.89 billion grew 19% year over year and came in about $60 million ahead of consensus. Adjusted earnings per share of $2.80 crushed the $2.50 estimate and grew 28% from the prior year. Gross margin guidance for the full year was raised, not cut. And yet the stock fell more than 12% the following day, breaking to levels not seen in two and a half years, and now sits roughly 40% below its recent high. A stock that entered the print already down 30% year to date got punished further for delivering a beat.

If you own the stock, that hurts. If you have been waiting for an entry point into one of the highest-quality medical robotics franchises ever built, this is the time that demands your attention. The question every investor should be asking is simple: did the business break, or did the narrative? My read, after going through the release, the earnings call, and the analyst reaction, is that the narrative got bruised while the machine underneath kept compounding. Let me walk through both sides.

What the Quarter Actually Showed

Start with the operating engine. Worldwide procedures across the da Vinci and Ion platforms grew approximately 16% in the quarter, with da Vinci procedures up about 15% and Ion procedures up roughly 36%. The company placed 468 da Vinci systems against 395 a year ago, and 246 of those were the flagship da Vinci 5, up 37% from 180 in the prior year quarter. The installed base, the single most important number in this entire story, grew 12% to 11,710 da Vinci systems worldwide, while the Ion installed base grew 21% to 1,096 systems. Combined, Intuitive now has nearly 13,000 robotic systems sitting inside hospitals and surgery centers around the world.

The financial quality of that growth remains exceptional. Recurring revenue, meaning the instruments, accessories, services, and leasing income that flow from every procedure performed, reached $2.47 billion and now represents 85% of total revenue. Non-GAAP operating margin came in at 42%. Free cash flow for the first half of 2026 was $1.8 billion, up 71% from the same period last year. The company ended the quarter with $8.6 billion in cash and investments, essentially no long-term debt, and still found room to repurchase $379 million of stock during the quarter. Very few companies of any size, in any industry, generate numbers like these.

One footnote on the earnings quality, because it matters for intellectual honesty: the quarter included a $28 million after-tax benefit, worth about $0.08 per share, from refunds of tariffs previously paid under the International Economic Emergency Powers Act. Strip that out and gross margin was 68.7% rather than the headline 70%. It was still a genuine beat, just a slightly smaller one than the press release suggests. Skeptics noticed, and they were right to.

So Why Did the Stock Fall Off a Cliff?

Three things spooked the investors, and each deserves to be taken seriously rather than waved away.

The first and most important is the slowdown in the United States. Domestic da Vinci procedure growth came in at 12%, a step down from recent quarters and below what analysts had modeled, while international procedures grew 20%. On the call, CEO Dave Rosa acknowledged that U.S. growth moderated from the company's own expectations at the start of the year, particularly in procedures that patients can defer. Management pointed to two culprits. Customers reported that the expiration of enhanced Affordable Care Act premium subsidies appears to be changing when patients seek care, as higher insurance costs push people to postpone elective surgery. Separately, bariatric procedures continued to decline in the high single digits as GLP-1 weight loss drugs absorb patients who might otherwise have chosen surgery. Neither headwind is within Intuitive's control, and the ACA effect in particular may build rather than fade as more patients feel the premium changes. It did not help that HCA Healthcare, the largest hospital operator in the country, flagged soft surgical volumes just two days before Intuitive reported. When the biggest hospital chain and the biggest surgical robotics company describe the same phenomenon in the same week, the market treats it as a sector signal, not a company hiccup.

The second issue was guidance. Intuitive Surgical maintained its full-year worldwide da Vinci procedure growth outlook of 13.5% to 15.5%, but added new language that it expects to land closer to the midpoint of that range. Do the arithmetic and the message is uncomfortable: with the first half running at roughly 15 to 16% growth, a midpoint outcome of around 14.5% for the year implies second-half growth decelerating toward 13%. Investors had positioned for a guidance raise. They got a subtle guide-down instead, and on a stock that is still trading at a premium multiple, that was enough to trigger a wave of price target cuts across Wall Street.

The third item was a strategic announcement that injected fresh uncertainty into the model. Management unveiled an Extended Use Program for a subset of EndoWrist instruments, planned for the first half of 2027, which will allow certain instruments to be used more times before replacement. The stated purpose is to lower the cost per procedure for benign cases and price-sensitive geographies. Strategically, this is sensible, arguably even necessary, as Medtronic's Hugo and Johnson & Johnson's Ottava prepare to compete partly on cost. But instruments and accessories generated $1.73 billion this quarter, roughly 60% of total revenue, and letting hospitals stretch instrument life is, by definition, a self-imposed headwind on that revenue line. Management has not yet finalized pricing and promised details on the next call. Markets hate unquantified changes to the most important revenue stream in a business model, and they discounted the stock accordingly.

Separating the Signal From the Noise

Here is where judgment comes in. Some of Friday's decline reflects real information. The U.S. deceleration is genuine, the demand headwinds from insurance costs and GLP-1 drugs are structural rather than one-quarter blips, and the Extended Use Program creates modeling uncertainty for 2027. Anyone telling you the drop was pure irrationality is not reading the transcript carefully.

A large portion of the move looks like the market doing what it always does to premium-multiple stocks: punishing them for being merely excellent instead of perfect. Consider what did not deteriorate. International procedure growth accelerated to 20%, with Europe and Asia each growing 20% and markets like India, Italy, Taiwan and the U.K. performing strongly. Da Vinci 5 demand remains robust, and the raised gross margin guidance directly refuted the bear argument that the new platform would dilute profitability. The platform grew procedures 61%. Ion grew 36% and has now crossed 400,000 cumulative procedures. U.S. system placements actually rose 24%, driven almost entirely by hospitals trading in older systems to upgrade, which is what an entrenched customer base voting with its capital budget looks like. The domestic slowdown is transient rather than structural, with deferred procedures representing postponed demand, not destroyed demand. A patient who delays a hernia repair or gallbladder surgery because of insurance costs still has the condition. That backlog eventually gets worked through, and history from prior deferral cycles supports this view.

The market is pricing the deceleration as if it were the beginning of the end. The evidence better supports a different interpretation: a temporary demand air pocket in one geography, layered on top of a valuation reset that was already underway all year for reasons that had little to do with the fundamentals.

The Moat the Market Is Discounting

Step back from the quarter and look at what an investor actually owns here, because this is where the long-term case has not changed at all.

The installed base is the crown jewel, and the numbers genuinely are eye-popping. Nearly 13,000 robotic systems are physically bolted into operating rooms across the globe, each representing a multi-million dollar capital commitment, months of installation and integration work, and, most importantly, a trained surgical staff. Tens of thousands of surgeons have built their skills, muscle memory, and clinical outcomes data on this platform. More than 15,000 surgeons have already operated on da Vinci 5 alone since its launch. A competitor does not simply need to build a comparable robot. It needs to convince a hospital to rip out functioning equipment, retrain its surgical teams, accept the clinical risk of a learning curve, and abandon a decade of workflow integration. This is switching cost as a business model, and it is why the razor-and-blade economics work: every one of those systems generates a growing annuity of instruments, accessories, and service revenue for as long as it operates. At 85% of revenue, that recurring stream gives Intuitive a revenue base with predictability that most industrial and technology companies can only envy.

The Ion story remains, in my view, the most underappreciated piece of the franchise. The market still values Intuitive primarily as a surgery company, but Ion extends the platform into diagnostics, enabling minimally invasive lung biopsies for early cancer detection. Procedures grew 36% this quarter, the installed base grew 21%, and the company has now placed systems in twelve countries outside the United States, with the international rollout still in its infancy. Lung cancer remains the deadliest cancer globally precisely because it is caught late. A platform that makes early biopsy safer and more accessible is not a side project; it is a second act that expands the total addressable market into an entirely new clinical category, using the same commercial infrastructure, the same hospital relationships, and the same recurring revenue economics that made da Vinci what it is.

Then there is the digital layer, which barely registers in most valuation models today. Every robotic procedure generates structured video, instrument kinematics, and outcomes data. Intuitive is steadily building connected offerings and analytics that help hospitals benchmark surgeons, improve outcomes, and run their programs more efficiently. Over time, this is the raw material for software and data-driven revenue streams and, plausibly, the largest surgical AI dataset in existence. It is optionality the market is currently handing to shareholders for approximately nothing.

The Financial Record and the Balance Sheet

The compounding record speaks for itself. Revenue has grown at roughly a 16% annual rate over the past decade, earnings per share at close to 19%, and both net income and free cash flow are at record levels, with first-half free cash flow up 71% this year alone. The balance sheet is a genuine fortress: $8.6 billion in cash and investments as of quarter end, effectively zero long-term debt, and cash growing every quarter even after buybacks and heavy capital investment. Return on invested capital has run above 19% for a decade, and nothing in the current results suggests that changes. Companies that sustain returns like that over ten-year periods are rare; companies that do it while self-funding their growth and carrying no leverage are rarer still.

Valuation: The Asymmetry Is Finally Here

For years the honest knock on ISRG was price. The stock routinely traded above 55 to 60 times forward earnings, and its five-year average multiple exceeded 58 times. That premium has now collapsed. After this decline, the shares trade at 30 on forward price to earnings, a level this stock has rarely visited in the past decade, for a business still growing revenue in the high teens with expanding gross margins and accelerating free cash flow. Wall Street's average price target, even after the barrage of cuts, sits far above the current quote, with the consensus in the mid-$500s.

Nobody can promise the bottom is in. The stock could stay weak while the market waits for evidence that U.S. procedure growth has stabilized, and the Extended Use pricing details in October are a genuine event risk. The risks are real: competition from Medtronic and Johnson & Johnson is finally arriving, China remains difficult with only two system placements this quarter and da Vinci 5 still not cleared on the mainland, tariffs could expand, and the insurance-driven softness in U.S. elective volumes could persist longer than the optimists expect.

Investing is about weighing what you pay against what you get. What you get here is a monopoly-grade installed base, an 85% recurring revenue model, a second growth platform in diagnostics, a debt-free balance sheet with $8.6 billion of firepower, a decade of 19%-plus returns on capital, and management that is willingly trading near-term revenue for long-term competitive position. What you pay is the lowest multiple this franchise has offered in years, compressed not by deteriorating economics but by a guidance sentence and a demand wobble in one geography.

That is the definition of an asymmetric setup for a patient, long-term investor. The quarter that scared the market is, on close inspection, the same quarter that showed the machine still compounding. When the fear is about timing and the facts are about durability, time is usually on the side of the owner.

Happy investing,
Stockscurrent Team